Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19
Oakville, Ontario--(Newsfile Corp. - May 6, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the filing of a new patent application covering the use of cannabidiol (CBD) to improve the outcome of patients with COVID-19. This new patent application includes the administration of CBD to reduce...
2020-05-06 8:09 AM EDT
Cardiol Therapeutics Announces Study Demonstrating its Proprietary Nanotechnology Targets Fibrous Tissue in the Heart
Oakville, Ontario--(Newsfile Corp. - April 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that data describing Cardiol's nanotechnology approach to drug delivery were submitted by the Company's international research collaborators and accepted for presentation at the American College of...
2020-04-14 7:27 AM EDT
Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
Oakville, Ontario--(Newsfile Corp. - April 1, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that data submitted by its international research collaborators were accepted for presentation at the American College of Cardiology's (ACC) 69th Annual Scientific Session & Expo together with the...
2020-04-01 7:27 AM EDT
Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, today filed its audited Year-end Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2019. Both are available under the Company's profile on SEDAR at www.sedar.com and on the...
2020-03-26 6:03 PM EDT
Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.
Oakville, Ontario--(Newsfile Corp. - March 18, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart disease, is pleased to announce that it has signed a supplier agreement to offer its pharmaceutically produced cannabidiol to Medical Cannabis by Shoppers ("Shoppers"), a subsidiary of Shoppers Drug Mart Inc. Shoppers will be the...
2020-03-18 7:27 AM EDT
Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation
Oakville, Ontario--(Newsfile Corp. - March 5, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart diseases, has received a No Objection Letter from Health Canada to conduct a Phase 1 study of the Company's pharmaceutically produced (cGMP), high concentration, pure cannabidiol formulation that is THC free (<5ppm). The Company...
2020-03-05 7:27 AM EST
Cardiol Therapeutics' Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada
Oakville, Ontario--(Newsfile Corp. - January 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that its exclusive manufacturing partner, Dalton Pharma Services ("Dalton"), has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada. This...
2020-01-15 7:12 AM EST
Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor
Oakville, Ontario--(Newsfile Corp. - December 18, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that it has appointed Michael J. Willner, Esq. as Business Advisor to the Company. Mr. Willner has been an active investor for over forty years and is the founder of Willner Capital, Inc., an...
2019-12-18 7:47 AM EST
Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors
Oakville, Ontario--(Newsfile Corp. - December 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately. Mr. Stott is the former Scientific Affairs Director, International and R&D Operations Director for GW...
2019-12-03 9:14 AM EST
Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency
Oakville, Ontario--(Newsfile Corp. - November 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol ("CBD") products and in the development of innovative cannabidiol medicines for heart disease, commented on Purisys, LLC's news release issued on November 21st which states that the U.S. Drug Enforcement Agency ("DEA") has removed their cannabinoid ingredients from Schedule I of the Controlled...
2019-11-25 8:37 AM EST
Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
Oakville, Ontario--(Newsfile Corp. - November 19, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) products and in the development of innovative cannabidiol medicines for heart disease, is pleased to announce the formation of the Clinical Steering Committee ("CSC") for a Phase 2 international trial in acute myocarditis using the Company's CardiolRx™100 cannabidiol formulation. The CSC,...
2019-11-19 7:02 AM EST
Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100
Oakville, Ontario--(Newsfile Corp. - October 1, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical CBD products and in the development of innovative CBD medicines for heart disease, announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation. CardiolRx 100 (100 mg/mL CBD with 3,000 mg of CBD per bottle) is designed to be the safest and most consistent...
2019-10-01 7:00 AM EDT
Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th
Oakville, Ontario--(Newsfile Corp. - September 5, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease, today announced that David Elsley, President & Chief Executive Officer, will present live at the KCSA Cannabis Investor Conference at VirtualInvestorConferences.com on Thursday, September 12th. Date: Thursday, September 12th Time: 12:00 -...
2019-09-05 3:36 PM EDT
Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
Oakville, Ontario--(Newsfile Corp. - July 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure, announces today that David Elsley, President and CEO of Cardiol, will be presenting at the Canaccord Genuity 39th Annual Growth Conference being held August 7-8, 2019 at the InterContinental...
2019-07-25 9:53 AM EDT
Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation
Oakville, Ontario--(Newsfile Corp. - June 20, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation. CardiolRx is Cardiol's pure pharmaceutically-produced CBD. Designed to be the safest...
2019-06-20 9:06 AM EDT
Cardiol Therapeutics Reports Results of its AGM
Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 12, 2019. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions...
2019-06-13 4:39 PM EDT
Cardiol Therapeutics to Webcast Annual General Meeting on June 12
Oakville, Ontario--(Newsfile Corp. - June 10, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it will be webcasting the informal portion of its annual general meeting (AGM) being held at Vantage Venues, 150 King Street West, 27th Floor, Toronto, on June 12, 2019, at 9:00 a.m. EDT. Following the...
2019-06-10 11:03 AM EDT
Cardiol Therapeutics' Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD
Oakville, Ontario--(Newsfile Corp. - June 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer of its pure pharmaceutical CBD, was selected to present at the Food and Drug Administration's (FDA)...
2019-06-03 8:03 AM EDT
Cardiol Therapeutics Commences Trading on the OTCQX
Oakville, Ontario--(Newsfile Corp. - May 30, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it has qualified to trade on the OTCQX® Best Market and begins trading today under the symbol "CRTPF". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on...
2019-05-30 8:33 AM EDT
Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the research and development of pharmaceutical cannabidiol and targeted therapies for inflammatory disease, today announced the filing of its audited year-end financial statements and management's discussion and analysis for the year ended December 31, 2018. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website...
2019-03-28 8:47 AM EDT